A223250 Share Price Performance
₩3,250.00
-125.00 (-3.70%)
Price ₩3,250.00
Share Price₩3,250.00
A223250 Community Narratives
There are no narratives available yet.
Recent A223250 News & Updates
No updates
DreamCIS, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 239.51
- Gross Margin
- 30.59%
- Net Profit Margin
- 9.36%
- Debt/Equity Ratio
- 1.0%
DreamCIS, Inc. Competitors
About A223250
- Founded
- 2000
- Employees
- 362
- CEO
- WebsiteView website
DreamCIS, Inc. provides clinical research services in South Korea. It offers clinical development services; biostatic, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -2.0%
- 3 Months: 20.9%
- 1 Year: 26.1%
- Year to Date: 28.6%
Over the last 7 days, the market has dropped 2.0%, driven by losses in the Materials and Information Technology sectors of 7.0% and 1.3%, respectively. As for the longer term, the market has actually risen by 26% in the last year. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading